Dose Escalation for SBRT of Recurrent VT Ventricular Tachyarrhythmia - a Single Center, Phase II Clinical Trial
Condition(s) studied
Investigational drug(s) / intervention(s)
Dose escalating stereotactic arrhythmia radioablation to treat ventricular tachycardia (VT): Dose escalating stereotactic arrhythmia radioablation to treat ventricular tachycardia (VT) refractory to conventional antiarrhythmic and catheter ablation-based therapy. First patients will be treated with a dose from 25 Gy prescribed to the 65-90% target volume encompassing isodose escalating to a maximum of 32.5 Gy prescribed to the 65-90% isodose.
Study summary
The objective of this study is to demonstrate that higher radiation doses are necessary to induce transmural scar formation which is currently assumed to be the underlying mechanism of successful long-term efficacy of VT treatment and therefore dose-escalation will lead to a significantly reduced long-term VT recurrence rate compared to the currently applied single dose of 25 Gy.
Eligibility
Primary outcome measure(s)
- safety measured by registered radiation associated adverse events up to 90 days — up to 90 days
safety measured by registered radiation associated adverse events
Trial sites (3)
| Facility | City | Region | Status |
|---|---|---|---|
| University Hospital Ostrava | Ostrava | Czechia | Recruiting |
| University Hospital Zurich | Zurich | Canton of Zurich | Recruiting |
| Inselspital Bern | Bern | Switzerland | Recruiting |
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05594368 on ClinicalTrials.gov ↗ ← All trials in Czechia